Literature DB >> 3934342

Differential proliferative responses of cultured Schwann cells to axolemma and myelin-enriched fractions. II. Morphological studies.

J H Meador-Woodruff, J E Yoshino, J W Bigbee, B L Lewis, G H Devries.   

Abstract

Axolemma-enriched and myelin-enriched fractions were prepared from bovine CNS white matter and conjugated to fluorescein isothiocyanate (FITC). Both unlabelled and FITC-labelled axolemma and myelin were mitogenic for cultured rat Schwann cells. Treatment of Schwann cells with the FITC-labelled mitogens for up to 24 h resulted in two distinct morphological appearances. FITC-myelin-treated cells were filled with numerous round, fluorescent-labelled intracellular vesicles, while FITC-axolemma-treated cells appeared to be coated with a patchy, ill-defined fluorescence, primarily concentrated around the cell body but extending onto the cell processes. These observations were corroborated under phase microscopy. Electron microscopy revealed multiple, membrane-bound, membrane-containing phagosomes within myelin-treated cells and to a far lesser extent in axolemma-treated cells. The effect on the expression of the myelin-mediated and axolemma-mediated mitogenic signal when Schwann cells were treated with the lysosomal inhibitors, ammonium chloride and chloroquine, was evaluated. The mitogenicity of myelin was reduced 70-80% by these agents whereas the mitogenicity of axolemma was not significantly altered under these conditions. These results suggest that axolemma and myelin stimulate the proliferation of cultured Schwann cells by different mechanisms. Myelin requires endocytosis and lysosomal processing for expression of its mitogenic signal; in contrast, the mitogenicity of axolemma may be transduced at the Schwann cell surface.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934342     DOI: 10.1007/bf01200801

Source DB:  PubMed          Journal:  J Neurocytol        ISSN: 0300-4864


  13 in total

1.  A career perspective on the discipline of neurochemistry.

Authors:  George H DeVries
Journal:  Neurochem Res       Date:  2009-01       Impact factor: 3.996

2.  T lymphocyte autoimmunity in peripheral nervous system autoimmune disease.

Authors:  C Linington; H Wekerle; R Meyermann
Journal:  Agents Actions       Date:  1986-12

3.  Sodium channels in the cytoplasm of Schwann cells.

Authors:  J M Ritchie; J A Black; S G Waxman; K J Angelides
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Macrophage-mediated myelin-related mitogenic factor for cultured Schwann cells.

Authors:  R R Baichwal; J W Bigbee; G H DeVries
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Schwann cells and myasthenia gravis. Preferential uptake of soluble and membrane-bound AChR by normal and immortalized Schwann cells, and immunogenic presentation to AChR-specific T line lymphocytes.

Authors:  Y P Zhang; S Porter; H Wekerle
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

6.  The role of potassium channels in Schwann cell proliferation in Wallerian degeneration of explant rabbit sciatic nerves.

Authors:  S Y Chiu; G F Wilson
Journal:  J Physiol       Date:  1989-01       Impact factor: 5.182

7.  Wallerian degeneration in ICAM-1-deficient mice.

Authors:  V I Vougioukas; S Roeske; U Michel; W Brück
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

8.  Mitogenic factors regulate ion channels in Schwann cells cultured from newborn rat sciatic nerve.

Authors:  G F Wilson; S Y Chiu
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

9.  Myelin phagocytosis in Wallerian degeneration. Properties of millipore diffusion chambers and immunohistochemical identification of cell populations.

Authors:  P Scheidt; R L Friede
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

10.  Changes in excitable membrane properties in Schwann cells of adult rabbit sciatic nerves following nerve transection.

Authors:  S Y Chiu
Journal:  J Physiol       Date:  1988-02       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.